© 2021 Marker Therapeutics, Inc.
It’s a dream many parents would welcome for their children: a vaccine that could prevent breast, ovarian and some lung cancers. It’s also the dream of immunology professor Dr. Keith Knutson. “The hope is we can develop vaccines before the development of cancer much in the way that we use a polio vaccine or a flu vaccine,” Dr. Knutson tells us in in his Mayo Clinic Jacksonville laboratory.
TapImmune, Inc. (NASDAQ: TPIV) announced today it has successfully completed a multi-gram scale-up and GMP manufacturing of a second clinical lot of TPIV 200, the company’s multi-epitope T-cell vaccine targeting folate receptor alpha.
Monday on First Coast Connect we spoke with former CIA operative and author T. L. Williams about his new novel and Chinese cyber hacking. We also heard from TapImmune CEO Glynn Wilson about a breast cancer study at the Mayo Clinic. WJCT’s Indie Endeavor host Ryan Benk and 1904 Music Hall co-owner Jason Hunnicut announced a new partnership at the downtown venue.
TapImmune, Inc. (NASDAQ: TPIV) today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for its patent application titled, “Chimeric nucleic acid molecules with non-AUG initiation sequences and uses thereof.”
If you’re a biotech investor who has not yet heard of TapImmune, Inc. (NASDAQ: TPIV), this clinical-stage immune-oncology company is charging its way through the sector with its cutting-edge vaccine technologies that are attacking ovarian and breast cancer with a whole new vengeance.
TapImmune, Inc. (NASDAQ: TPIV) announced today it has successfully completed a multi-gram scale-up and GMP manufacturing of a second clinical lot of TPIV 200, the company’s multi-epitope T-cell vaccine targeting folate receptor alpha.